Our site uses cookies to make navigation as function as possible, including “third party” cookies and “profiling cookies” designed to tailor
on-line contents to suit the preferences expressed while surfing the internet. Should you wish to receive more information, or deny your
consent to some or all cookies, click here. If you proceed with browsing this website, you will be consenting to the use of all cookies.

美纳里尼基金会

该基金会成立于 1976 年...

GO TO SITE

美纳里尼在亚太地区

搜索我们的公司

主要品牌

最新动态

November 04 2021

Menarini Receives FDA Orphan Drug Designation for SEL24/MEN1703, a first in class, dual PIM/FLT3 inhibitor for the Treatment of Acute Myeloid Leukemia

Read More
October 21 2021

Menarini Group and Radius Health Announce Positive Phase 3 Topline Results from the EMERALD Trial Evaluating Elacestrant in Breast Cancer

Read More
October 21 2021

Menarini Group and Radius Health Announce Positive Phase 3 Topline Results from the EMERALD Trial Evaluating Elacestrant in Breast Cancer

Read More
August 23 2021

Menarini Enters into an Exclusive Licensing Agreement with Daiichi Sankyo to Commercialise TARLIGE® in Singapore, Malaysia, and the Philippines

Read More
July 22 2021

美纳里尼亚太公司收购礼来公司希爱力®Cialis®品牌(他达拉非) 增强美纳里尼中国男性健康产品线

Read More